Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Georgina Jones Suzuki

Of Counsel

Palo Alto +1 650 632 4708

  • About
  • Representative Matters
  • Credentials
  • About

    Georgina Jones Suzuki is a life sciences collaboration and licensing lawyer who advises pharmaceutical, biotechnology, medical device, diagnostics, and digital health companies on complex strategic transactions.

    Georgina helps life sciences companies structure, negotiate, and execute collaborations, licensing agreements, technology transfer arrangements, joint ventures, mergers and acquisitions, divestitures, supply and distribution agreements, and other commercial transactions that are critical to bringing lifechanging technologies to market. She regularly advises clients on matters involving drug development, biotechnology platforms, medical technologies, diagnostics, digital health, data, machine learning, and artificial intelligence.

    Clients turn to Georgina for practical, solutions-oriented guidance on high-stakes life sciences collaborations and licensing transactions. Her experience includes a secondment at a global pharmaceutical company, giving her firsthand insight into how life sciences organizations evaluate opportunities, manage legal and business risk, and make strategic decisions.

    Georgina is recognized by Chambers as “Up and Coming” in California in Life Sciences: Corporate/Commercial (2026) and has been named a “Woman Leader in Tech Law” in California (2025) for her achievements in the life sciences sector. Clients praise her for providing “the highest level of service and legal sophistication” and “trust her awareness and knowledge of the legal issues involved in life science licensing transactions.”

    Areas of Expertise

  • Practices and Industries
  • Representative Matters

    Life Science Collaborations and Licensing

    • Represented Johnson & Johnson, Gilead Sciences, and other pharmaceutical companies in connection with numerous strategic collaboration agreements with biotechnology companies.
    • Represented Gilead Sciences in licensing and collaboration matters in connection with its exclusive option to acquire Pionyr Immunotherapeutics Inc.
    • Advised Sanofi in a collaboration and global license agreement with EVOQ Therapeutics to develop autoimmune disease therapies by activating regulatory T cells using EVOQ’s NanoDisc technology focused on restoring the body’s natural immune tolerance pathways in a deal worth over $500 million.
    • Represented Roivant Sciences on the foundational license for a TL1A directed antibody from Pfizer to Telavant, a Roivant company focused on the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Roche subsequently purchased Telavant for $7.1 billion upfront plus contingent consideration.
    • Represented Takeda Pharmaceutical Company Limited in a collaboration and license agreement worth up to $900M with Turnstone Biologics directed towards the development and commercialization of a leading oncolytic candidate.
    • Advised South Korean biotechnology company SK Biopharmaceuticals in a global licensing agreement, valued at up to $571.5 million, with radiotherapy company Full-Life Technologies for exclusive worldwide clinical research, development, manufacturing and commercialization rights to Full-Life’s FL-091 radiopharmaceutical compound.
    • Advised Bain Capital on IP matters in connection with its formation of Cerevel Therapeutics, a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. Counseled Bain on the contribution of pre-commercial neuroscience assets to Cerevel by Pfizer Inc.
    • Represented a leading biopharmaceutical company in a multi-target option and collaboration agreement with potential payments over $2 billion with Nurix Therapeutics to discover targeted protein degradation drugs for the treatment of cancer using Nurix’s proprietary platform involving E3 ligases that induce degradation of drug targets. The licensee has the option to exclusively license drug candidates from each target program, with Nurix retaining the option for a profit share and a co-promotion arrangement in the United States.
    • Represented a leading pharmaceutical company in a strategic collaboration to identify biomarkers associated with clinical response in up to five pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease.
    • Represented a leading pharmaceutical company in a collaboration and license agreement with a Belgium research university to develop potential treatments for respiratory syncytial virus (RSV) infection.
    • Represented a leading pharmaceutical company in an exclusive worldwide license and collaboration agreement with potential payments over $400 million with a biotechnology company to develop and commercialize the licensor’s leading gene therapy product candidates, together with additional pipeline candidates, for the treatment of inherited retinal diseases.
    • Represented G1 Therapeutics in a global licensing agreement, excluding the Asia Pacific region, with Pepper Bio for lerociclib for all indications except for certain radioprotectant uses.

    Digital Health Transactions

    • Represented many digital health companies pioneering innovative technology including artificial intelligence, machine learning, data analytics, next‑generation sequencing, and biomedical engineering including Johnson & Johnson, TRex Bio, Prellis Biologics, NeoGenomics, and others.
    • Represented Genesis Molecular AI, a Stanford University spin-out company with a focus on artificial intelligence, in a multi-target collaboration (based on using Genesis’s AI-driven drug discovery platform to identify new drug candidates) with Genentech, a member of the Roche Group.
    • Represented Atomwise, an artificial intelligence-based drug discovery company, in a partnership with GC Pharma to discover and develop novel hemophilia therapies.
    • Represented Iterative Scopes, a growing leader and pioneer in computational gastroenterology, on licensing matters for use of its artificial intelligence precision medicine platform that leverages advanced machine learning and computer vision to interpret endoscopic images and other data.
    • Advised a leading research institution on a complex cross-border deal involving human genomic data.

    Life Science and Health Care Strategic Transactions

    • Represented Eli Lilly in its $2.5 billion acquisition of Scorpion Therapeutics, immediately following a spin-off of non-core Scorpion assets.
    • Represented Becton, Dickinson and Company, BD, in a definitive agreement to acquire Edwards Lifesciences' Critical Care product group, a leader in advanced hemodynamic monitoring solutions, for $4.2 billion in cash.
    • Advised TPG on intellectual property matters in its $2 billion sale of Immucor, Inc., which has a global presence in transfusion and transplant in vitro diagnostics, to Werfen.
    • Advised KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, a global medical technology company, in its entry into a merger agreement with Asensus Surgical, Inc. that will create a leading surgical robotics division within KARL STORZ.
    • Represented a consortium led by Silversmith Capital Partners and Health Velocity Capital in a majority investment in Fortified Health Security, a managed security services provider to the health care industry.
    • Represented Patient Square Capital on IP matters in various strategic investments, including its investment in hearing loss medical device company Eargo, Inc.

    Areas of Expertise

  • Credentials
    Education
    • Boston University School of Law, J.D., 2014
        • cum laude
        • Boston University Law Review, Member
    • Georgetown University, B.S.F.S., 2007
        • magna cum laude
    Bar Admissions
    • California
    Accolades
    • Chambers USA, Up and Coming : Life Sciences: Corporate/Commercial (2026)
    • The Recorder’s California Legal Awards: Women Leaders in Tech Law, Intellectual Property (2025)
    • Best Lawyers in America – Ones to Watch (2022-2026)

    Areas of Expertise

News and Insights

Events